What is the nature of the 2,286-share award reported by Abbott (ABT) director Stratton?

The 2,286-share award is a restricted stock unit grant under the Abbott Laboratories 2026 Incentive Stock Program. It will be paid in Abbott common shares on a one-to-one basis, rather than being an immediate cash or stock transaction at a market price.

Abbott Laboratories (NYSE: ABT) director granted 2,286-share RSU award

Q: How many Abbott (ABT) shares does John G. Stratton hold after this award?

After this transaction, John G. Stratton directly holds 21,319 Abbott common shares . This total includes the 2,286-share restricted stock unit award reported, reflecting his updated direct ownership position as shown in the Form 4 filing.

Q: Did John G. Stratton buy Abbott (ABT) shares on the open market in this Form 4?

No. The Form 4 shows a grant/award acquisition of 2,286 shares at a reported price of $0.00 per share. This reflects a compensation grant of restricted stock units, not an open-market purchase using personal funds.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Stratton John G reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories director John G. Stratton received an award covering 2,286 common shares as a grant of restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. Following this award, he holds 21,319 common shares directly.

The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. This is a compensation-related equity grant rather than an open-market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stratton John G

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 21,319 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU award size: 2,286 shares Price per share for award: $0.00 per share Shares owned after transaction: 21,319 shares

3 metrics

RSU award size 2,286 shares Restricted stock unit grant to director Stratton

Price per share for award $0.00 per share Reported transaction price for the RSU grant

Shares owned after transaction 21,319 shares Total common shares directly held by Stratton after award

Key Terms

Restricted stock unit, 2026 Incentive Stock Program, change in control

3 terms

Restricted stock unit financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2026 Incentive Stock Program financial

"award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

04/28/2026 - 07:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stratton John G

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

ILLINOIS

60064

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares without par value	04/24/2026		A		2,286⁽¹⁾	A	$0	21,319	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ John G. Stratton by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Abbott Laboratories (ABT) director John G. Stratton report in this Form 4?

John G. Stratton reported receiving an equity award covering 2,286 Abbott common shares as restricted stock units. The grant is part of the Abbott Laboratories 2026 Incentive Stock Program and represents compensation, not an open-market stock purchase or sale.

How many Abbott (ABT) shares does John G. Stratton hold after this award?

After this transaction, John G. Stratton directly holds 21,319 Abbott common shares. This total includes the 2,286-share restricted stock unit award reported, reflecting his updated direct ownership position as shown in the Form 4 filing.

When will John G. Stratton receive the Abbott (ABT) shares from this RSU award?

The restricted stock unit award will be paid in Abbott common shares on the earlier of the director’s separation from service, death, or a change in control of the company, as defined in the 2026 Incentive Stock Program.

Did John G. Stratton buy Abbott (ABT) shares on the open market in this Form 4?

No. The Form 4 shows a grant/award acquisition of 2,286 shares at a reported price of $0.00 per share. This reflects a compensation grant of restricted stock units, not an open-market purchase using personal funds.